Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The hemozoin formation process is a critical detoxification pathway within the acidic digestive vacuole of Plasmodium parasites, particularly Plasmodium falciparum [1]. During the intraerythrocytic stage of its life cycle, the parasite degrades host hemoglobin to obtain essential amino acids, a process that releases large amounts of free heme (ferriprotoporphyrin IX) [2]. Free heme is highly toxic to the parasite, as it can destabilize cell membranes and inhibit various enzymes through oxidative damage [3]. To survive, the parasite converts this toxic heme into an insoluble, chemically inert crystalline form known as hemozoin, or malaria pigment [1]. This biocrystallization is facilitated by the acidic environment of the vacuole and potentially by parasite-derived proteins like the Heme Detoxification Protein (HDP) [2]. This process serves as the primary therapeutic target for several classes of antimalarial drugs, most notably the 4-aminoquinolines such as chloroquine and the quinoline methanols like quinine [4]. These drugs interfere with the crystallization process by binding to heme monomers or the surface of growing hemozoin crystals, preventing further sequestration of toxic heme [3]. The resulting accumulation of free heme leads to the destruction of the parasite's digestive vacuole and subsequent cell death [4]. While highly effective, the utility of drugs targeting this process is increasingly threatened by the development of resistance, often mediated by mutations in the Plasmodium falciparum chloroquine resistance transporter (PfCRT) [1]. Sources: [1] Egan, T. J. (2008). Recent advances in understanding the mechanism of hemozoin (malaria pigment) formation. Future Microbiology, 3(1), 77-87. [2] Jani, D., et al. (2008). HDP—a potent catalyst of hemozoin formation in Plasmodium. PLoS Pathogens, 4(1), e1000053. [3] Sullivan, D. J., et al. (1996). Quinoline antimalarial drugs inhibit spontaneous formation of beta-hematin. Journal of Biological Chemistry, 271(34), 20403-20409. [4] StatPearls (2023). Antimalarial Medications. Treasure Island (FL): StatPearls Publishing.
Inhibition of the biocrystallization of toxic free heme (ferriprotoporphyrin IX) into non-toxic hemozoin crystals, leading to the accumulation of free heme which causes oxidative stress and membrane damage to the parasite.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hemozoin formation process.